Key Drivers
- Liquidity Buffer
- Profitability Weakness
- Negative Cash Flow
AIAI Summary
TLRY is shifting from a pure U.S. legalization proxy to a real turnaround story driven by improving international cannabis and pharma/distribution, but with still-negative cash flow, thin margins, and a persistent downtrend, the stock is only actionable if management can sustain margin expansion and convert revenue mix improvement into self-funding profitability.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Buffer
- •Profitability Weakness
- •Negative Cash Flow
TLRY looks cheaply valued with a reasonably solid balance sheet, but persistent losses, negative cash flow, and poor returns still point to ongoing fundamental weakness. ക ക
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support cluster
- •Weak rebound
TLRY remains in a clear downtrend over the last month, with lower highs/lows and a ~23% drop to $5.31, though the recent $5.40-$5.50 cluster suggests near-term support and a possible bounce if $5.30-$5.50 holds.
Extended selloff from $6.86 to $5.31 after a $7.87 peak indicates persistent downside pressure
Sentiment & News
Key News Insights:
- •Policy Whiplash
- •Insider Selling
- •Weak Support
Tilray's stock has been whipsawed by shifting U.S. cannabis policy hopes, but insider selling, fading rescheduling momentum, and weak technicals have kept the broader outlook under pressure.
The news flow points to continued volatility and limited upside unless U.S. cannabis regulation becomes clearer and fundamentals improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings